Levels of TNF-alpha, IL-6, sICAM-1, sVCAM-1 in NSCLC patients plazma Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008
Soluble interleukin 2 receptor ( sIL-2R ) during chemotherapy of the lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
The levels of osteoprotegerin (OPG), interleukin 18 (IL-18) and soluble interleukin 2 receptor (sIL-2R) in serum during chemotherapy of lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 318s Year: 2004
Late-breaking abstract: Serum concentrations of new factors (IL-20, galectin 3, IL-29 and IL-33) involved in angiogenesis in patients with advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2011 - Innovative diagnostic methods for lung cancer Year: 2011
Serum levels of sFas and sFasL during chemotherapy of lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 329s Year: 2005
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Pro- and anti-inflammatory cytokines TNF-alpha, IFN-gamma, IL-10 and TGF-beta1 levels in blood serum as markers of plasmaferesis success and inflammation activity in lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 676s Year: 2006
Levels of interleukins IL-4, IL-6, IL-8 and TNFa in sera of patients with tuberculosis before and during treatment Source: Eur Respir J 2002; 20: Suppl. 38, 556s Year: 2002
Decreased levels of CXC angiogenic chemokines (IL-8, ENA-78 and GRO-α) in BALF after interferon gamma-1b treatment in IPF patients Source: Eur Respir J 2005; 26: Suppl. 49, 267s Year: 2005
Content of IL-6, IL-10, TNF-α and leptin in blood of COPD patients depending on stage of disease Source: Eur Respir J 2007; 30: Suppl. 51, 769s Year: 2007
The neoadjuvant therapy of NSCLC down-regulates serum levels of growth factors (VEGF, bFGF, TGF-beta) with no effect on apoptosis (CD95L) and local tumour invasiveness markers (TIMP-1) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Serum levels of IL-10 and IL-12 i patients with pulmonary sarcoidosis Source: Annual Congress 2009 - Inflammation and airways Year: 2009
Different Th1 and Th2 citokine profile in serum and tumor microciculation of SCLC and NSCLC patients Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018
TNF-a and IL-10 control macrophage expression of CXCL13, a prognostic biomarker of idiopathic pulmonary fibrosis Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018
YKL-40, soluble IL-2 receptor, ADA and neopterin: comparison of markers of sarcoidosis activity Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009
IL-9 and IL-9 receptor (IL-9r) expression in BALF lymphocytes in ILD patients: preliminary results. Source: International Congress 2017 – The wide spectrum of ILDs Year: 2017
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients Source: Eur Respir J 2003; 22: Suppl. 45, 251s Year: 2003
Serum TNF-a, IL-12 and IL-13 levels in severe bronchial asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 353s Year: 2004
The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage (BAL) in lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004
TNF-alpha, IL-8, IL-6 levels in serum of sarcoidosis patients with different clinical course Source: Annual Congress 2013 –Sarcoidosis and other granulomatosis Year: 2013